Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | MicrobiomeTrials← Back to trialsNCT06011109
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-12-13Est. Completion: 2026-12-31
Enrollment target: 30 participants Locations- Mayo Clinic, Rochester, Minnesota, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
Other microbiome trials you might be interested in
Glioma
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 …
Orange, United StatesEst. completion Aug 9, 2027
Glioblastoma Multiforme of BrainGliomaGlioblastoma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose o…
Tampa, United StatesEst. completion Jun 2027
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/…
Birmingham, United StatesEst. completion Jun 2028